NASDAQ: ANIPAni Pharmaceuticals Inc Stock
$81.34-0.43 (-0.53%)
Updated Dec 8, 2025
ANIP Price
$81.34
Fair Value Price
N/A
Market Cap
$1.83B
52 Week Low
$52.50
52 Week High
$99.50
P/E
47.57x
P/B
3.61x
P/S
2.34x
PEG
0.62x
Dividend Yield
N/A
Revenue
$826.88M
Earnings
$40.57M
Gross Margin
61.1%
Operating Margin
8.73%
Profit Margin
4.7%
Debt to Equity
1.78
Operating Cash Flow
$171M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ANIP Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANIP's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ANIP
Ranked#12 of 57
Ranked#12 of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.91 | A | |
| $3.47 | A | |
| $36.60 | A |
Be the first to know about important ANIP news, forecast changes, insider trades & much more!
ANIP News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANIP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIP ($81.34) is trading above its intrinsic value of $58.17, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANIP is poor value based on its earnings relative to its share price (47.57x), compared to the US market average (45.87x)
P/E vs Market Valuation
ANIP is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ANIP due diligence checks available for Premium users.
Valuation
ANIP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
47.57x
Industry
-5.84x
Market
45.87x
ANIP is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ANIP is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ANIP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.61x
Industry
2.22x
ANIP is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIP price to earnings growth (PEG)
For valuing profitable companies with growth potential
ANIP is good value based... subscribe to Premium to read more.
PEG Value Valuation
ANIP's financial health
Profit margin
Revenue
$227.8M
Net Income
$26.6M
Profit Margin
11.5%
ANIP's Earnings (EBIT) of $72.21M... subscribe to Premium to read more.
Interest Coverage Financials
ANIP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$902.3M
Debt to equity
1.78
ANIP's short-term assets ($698.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIP's short-term assets ($698.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANIP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$44.1M
Investing
-$6.2M
Financing
$6.3M
ANIP's operating cash flow ($170.72M)... subscribe to Premium to read more.
Debt Coverage Financials
ANIP vs Pharmaceutical Stocks
Ani Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.